Search research articles
Contact Us
Filters
Showing results (51-60 of 124) with videos related to
Page
of 13
Sort By:
Journal of the Neurological Sciences
|
April 9, 2018
Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients
Lucie Kadrnozkova, Manuela Vaneckova, Lukas Sobisek, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 13, 2015
Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later
Tomas Uher, Dana Horakova, Michaela Tyblova, et al.
BMC Neurology
|
July 28, 2016
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
Ralf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, et al.
Journal of Neurology
|
April 8, 2022
Time course of lesion-induced atrophy in multiple sclerosis
Keith Carolus, Tom A Fuchs, Niels Bergsland, et al.
Journal of Lipid Research
|
August 6, 2015
Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients
Kelly Fellows, Tomas Uher, Richard W Browne, et al.
Journal of the Neurological Sciences
|
December 3, 2014
Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment
Tomas Uher, Ralph H B Benedict, Dana Horakova, et al.
Journal of Neurology
|
October 20, 2011
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS
Bianca Weinstock-Guttman, Steven L Galetta, Gavin Giovannoni, et al.
The New England Journal of Medicine
|
September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
Robert J Fox, David H Miller, J Theodore Phillips, et al.
The Lancet. Neurology
|
February 10, 2009
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
Eva Havrdova, Steven Galetta, Michael Hutchinson, et al.
Journal of Neuroimmunology
|
May 31, 2011
HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event
Dana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 124) with videos related to
Sort By:
Page
of 13
Journal of the Neurological Sciences
|
April 9, 2018
Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients
Lucie Kadrnozkova, Manuela Vaneckova, Lukas Sobisek, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 13, 2015
Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later
Tomas Uher, Dana Horakova, Michaela Tyblova, et al.
BMC Neurology
|
July 28, 2016
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
Ralf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, et al.
Journal of Neurology
|
April 8, 2022
Time course of lesion-induced atrophy in multiple sclerosis
Keith Carolus, Tom A Fuchs, Niels Bergsland, et al.
Journal of Lipid Research
|
August 6, 2015
Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients
Kelly Fellows, Tomas Uher, Richard W Browne, et al.
Journal of the Neurological Sciences
|
December 3, 2014
Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment
Tomas Uher, Ralph H B Benedict, Dana Horakova, et al.
Journal of Neurology
|
October 20, 2011
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS
Bianca Weinstock-Guttman, Steven L Galetta, Gavin Giovannoni, et al.
The New England Journal of Medicine
|
September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
Robert J Fox, David H Miller, J Theodore Phillips, et al.
The Lancet. Neurology
|
February 10, 2009
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
Eva Havrdova, Steven Galetta, Michael Hutchinson, et al.
Journal of Neuroimmunology
|
May 31, 2011
HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event
Dana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, et al.
Page
of 13